欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (2): 164-166.

• 临床研究 • 上一篇    下一篇

伊贝沙坦治疗慢性充血性心力衰竭的临床研究

谭健强   

  1. 广东省开平市第一人民医院心内科, 开平 529300
  • 收稿日期:2001-12-31 修回日期:2002-03-04 出版日期:2002-04-26 发布日期:2020-11-27
  • 通讯作者: 谭健强, 男, 副主任医师, 心内科副主任, 从事心内科临床工作。Tel:0750-2391111  E-mail:kptjq@21cn.com

Clinical investigation of irbesartan in treatment of chronic congestive heart failure

Tan Jian-Qiang   

  1. Department of Cardidogy, First People's Hospital of Kaiping, Kaiping 529300
  • Received:2001-12-31 Revised:2002-03-04 Online:2002-04-26 Published:2020-11-27

摘要: 目的: 评价伊贝沙坦(irbesartan) 治疗慢性充血性心力衰竭的疗效和安全性。方法: 80 例慢性充血性心力衰竭患者随机分为常规治疗组(对照组) 和伊贝沙坦组(治疗组), 各40 例, 常规治疗组应用洋地黄、利尿剂、扩张血管药物常规治疗, 伊贝沙坦组在常规治疗基础上口服伊贝沙坦75 ~ 300 mg·d-1,12 wk 一疗程。结果: 与常规治疗组比较, 临床症状和心功能明显改善(P<0.01), 左室射血分数增加、左室重量减轻(P<0.05), 不良反少且轻微。结论: 在常规治疗基础上, 加用伊贝沙坦治疗慢性充血性心力衰竭疗效好且安全。

关键词: 伊贝沙坦, 心力衰竭, 左室射血分数, 左室重量

Abstract: AIM: To evaluate the therapeutic effect and safety of irbesartan in treatment of chronic congestive heart failure.METHODS: 80 patients with chronic congestive heart failure were randomizedly divided into the irbesartan group and the routine group, 40 cases in every group.The routine group was treated with nomal treatment digtoxin ethacrynicum and dilation vasocular, and the irbesartan group was treated with irbesartan 75-300 mg one time daily based on the nomal treatment.The course of treatment was 12 weeks.RESULTS: Irbesartan could improve symptom and heart function clearly (P< 0.01), and inccrease left ventricular ejection faction (LVEF).The reverse left ventricular mass weigh decreased more significantly than routine group (P< 0.05).Little side effect was found.CONCLUSION: Irbesartan has better curative effect and safety in patients with chronic congestive heart failure.

Key words: irbesartan, heart failure, left ventricular ejection faction, left ventricular mass weigh

中图分类号: